Startups
Biotechnology Industry Partnership Programme (BIPP) is a government partnership with Industries for support on a cost sharing basis for path-breaking research in frontier futuristic technology areas having major economic potential and making the Indian industry globally competitive. It is focused on IP creation with ownership retained by Indian industry and wherever relevant, by collaborating scientists. BIPP supports the development of appropriate technologies in the context of recognized national priorities in the area of agriculture, health, bio-energy, green manufacturing, when the scale of the problem has serious consequences for social and economic development. BIPP is an Advanced Technology Scheme only for high risk, transformational technology/ process development. It is for high risk futuristic technologies and mainly for viability gap funding. The uniqueness of this scheme is that it is for "Break through research" which enables product and process development and is patentable, with IP ownership rights resting with industry.
Eligibility: An Indian company, whether small, medium, or large with a DSIR-recognised in-house R&D unit, is eligible under this scheme. Also, a joint association of an Indian company and national R&D organisations and institutions; as well as a group of Indian companies along with national research organisations are eligible.
Funding Grant: The eligible stakeholders are provided support for high-risk, accelerated technology development especially in futuristic technologies. Support is also provided for companies working in very high-risk, nationally- and socially-relevant areas, with no assured market. It provides for product evaluation and validation through support for limited and large-scale field trial for agriculture products and clinical trials (Phase I, II, III) for health care products and also supports research project for novel IP generation.
Time Period: There are three calls for proposals in a year: February 15–March 31, June 15–July 31 and October 15–November 30.